Published • loading... • Updated
FDA grants J&J accelerated approval for head and neck cancer treatment - Regional Media News
The approval was based on a 102-patient trial in which 42% of treated patients saw their tumors shrink or disappear, the FDA said.
Summary by regionalmedianews.com
7 Articles
7 Articles
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1
FDA grants J&J accelerated approval for head and neck cancer treatment
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources7
Leaning Left0Leaning Right2Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
C 71%
R 29%
Factuality
To view factuality data please Upgrade to Premium
